DOCSLIB.ORG

Pharmacological Study of Aprindine (A. Christiaens, AC1802; N-(3-Diethylamino) Propyl)-N-Phenyl-2-Indanamine) by Georges Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacological Study of Aprindine (A. Christiaens, AC1802; N-(3-Diethylamino) Propyl)-N-Phenyl-2-Indanamine) by Georges Et Al Japan. J. Pharmacol. 25, 549-561 (1975) 549 ANTIARRHYTHMIC EFFECT OF APRINDINE ON SEVERAL TYPES OF VENTRICULAR ARRHYTHMIAS Motohiko UEDA, Sadatoshi KIMOTO, Saburo MATSUDA, Masaru KAWAKAMI, Eiichi MORISHIGE, Shoichi MATSUMURA and Hiroshi TAKEDA Shionogi Research Laboratory, Shionogi & Co., Ltd., Fukushima-ku, Osaka 553, Japan Accepted July 31, 1975 Abstract-The antiarrhythmic effect of aprindine was compared with those of lidocaine and propranolol on several ventricular arrhythmias-epinephrine arrhythmias in cats, ouabain arrhythmias in cats and guinea pigs, ischemic ventricular arrhythmias in coronary-ligated Beagle dogs. Antiarrhythmic effects of aprindine and lidocaine were observed both in ouabain and ischemic arrhythmias, but not in epinephrine arrhythmias. While propranolol had a strong antiarrhythmic effect against epinephrine and ouabain arrhythmias, it did not increase sinus beats in ischemic arrhythmias. Marked anti arrhythmic effects of aprindine in ischemic arrhythmias were observed in dogs using either single intravenous administration (4 mg, kg) or intravenous infusion (200 pg/ kg/min, 2 mg/kg). Antiarrhythmic activity of aprindine is considered to be about twice as strong as that of lidocaine, but lidocaine is less toxic in experimental animals. Pharmacological study of aprindine (A. Christiaens, AC1802; N-(3-diethylamino) propyl)-N-phenyl-2-indanamine) by Georges et al. (1) showed that the antiarrhythmic effects of aprindine were present both in ouabain arrhythmias and ischemic ventricular arrhythmias in dogs. These workers also reported the superior local anesthetic activity of aprindine to lidocaine, tetracaine, and procaine. Fasola (2) and Kesteloot et al. (3) clinically confirmed the antiarrhythmic effect of aprindine, i.e., prevention of premature ventricular beats. From electrocardiograms of arrhythmic patients, Gleichmann et al. (4) observed that aprindine as well as ajmaline retarded conduction in the His bundle. Orally administered aprindine is said to be more favorable than intravenously administered lidocaine for ventricular arrhythmias in patients with acute myocardial infarction (5). We compared antiarrhythmic effects of aprindine on several ventricular arrhythmias in cats, guinea pigs and dogs with those of lidocaine, propranolol, ajmaline, quinidine, and procaine amide. MATERIALS AND METHODS Epinephrine arrhythmias: Male cats weighing 2.2-5.2 kg were anesthetized with pentobarbital-Na (25 mg/kg, i.v.) and urethane (0.6 g/kg, s.c.). Respiratory movements via a glass cannulae inserted into trachea, femoral blood pressure, and electrocardiogram (ECG II, V5_6) were recorded on an ink-writing oscillograph (WI-260, Nihon Kohden) 550 M. UEDA ET AL. with a respiratory pick-up (MTR-ITA, N.K.), a pressure transducer (MP-24T, N.K.), and a biophysical amplifier (RB-2, N.K.), respectively. FIG. 1. Chemical structure of aprindine Rapid intravenous injection of epine hydrochloride phrine (30-50 fig/kg) elicited marked ventric ular arrhythmias lasting for 1 to 1.5 min in anesthetized cats. Five min after the intravenous administration of antiarrhythmic compounds, epinephrine was injected. In order to com pare the antiarrhythmic effect, sinus (SR) and non-sinus rates (NSR) caused by epinephrine were observed every 30 sec for a duration of 5 min before and after administration of the antiarrhythmic agent. The duration of the antiarrhythmic effects was confirmed by re peated administration of epinephrine at 30 and 60 min after the antiarrhythmic compounds. Ouabain arrhythmias in cats: Ouabain was intravenously administered to anesthetized cats until steady occurrence of ventricular rhythm-that is, the initial ouabain dose (50 fig/kg) was followed by an additional dose of 5 Pg/kg every 15 min. Antiarrhythmic compounds were intravenously or orally administered 15-30 min after the establishment of ventricular rhythm in cats. Intravenous infusion of the antiarrhythmic compound was performed with an infusion pump (STP-11, Sharp) until 3-5 min after the disappearance of arrhythmias. Ouabain arrhythmias in guinea pigs: Ouabain at a dose of 4.4 ,ug/animal was inter mittently administered every 2 min to anesthetized male guinea pigs weighing 330-430 g (urethane 1.3-1.6 g/kg, i.p.) until cardiac arrest following the method of Sekiya and Vaughan Williams (6). In order to differentiate ventricular arrhythmias, ECG II of guinea pig was continuously recorded with ink-writing oscillograph. The ouabain dose which caused ventricular extrasystole, ventricular rhythm, ventricular fibrillation, and cardiac arrest was statistically compared (F-test) between the control group and the group given antiarrhythmic compounds intravenously (5 min) or intraduodenally (10 min) before ouabain. Ischemic arrhythmias: Beagle dogs of either sex weighing 7-10 kg were anesthetized with morphine (1 mg/kg, s.c.) and pentobarbital-Na (25 mg/kg, i.p.). After thoracotomy under artificial respiration with room air, the anterior descending branch of the left coronary artery was ligated at the inferior margin of the left atrium by Harris' technique (7). Twenty four hr after the operation, marked ventricular arrhythmias were continuously noted on the ECG II in the conscious dogs. ECG II was recorded with the ink-writing oscillograph, as antiarrhythmic compounds were being injected or infused (KN-202, Natsume) into the cutaneous vein of the fore-leg. SR and NSR every I min were counted in order to evaluate the antiarrhythmic activity of the compounds. Compounds: The following compounds were used as saline solutions: aprindine HC1 (A. Christiaens), dl-propranolol• HCl (Sigma), procaine amide' HCl (K & K Labs.), quinidine• H$SO4 (Merck), lidocaine (K & K Labs.), ajmaline (Yamanouchi), epinephrine Cl (Sankyo), ouabain (Merck). Lidocaine was dissolved with 1N hydrochloric acid solution and diluted with saline solution after the pH had been adjusted to 5.5 to 7.0 with solid ANTIARRHYTHMIC EFFECT OF APRINDINE 551 sodium bicarbonate. The dosage of a given compound was determined as a base. RESULTS Effects on epinephrine arrhythmias in cats Intravenous injection of 3 mg/kg aprindine or ajmaline caused transient apnoea and a marked fall of blood pressure with ventricular arrhythmias lasting for a few min. Though lidocaine (4 mg/kg, i.v.) caused transient apnoea as well, only a moderate fall of blood pressure was observed without noticeable changes in ECG pattern. Thus the maximal doses used for this experiment were 2 mg/kg for aprindine and 4 mg/kg for lidocaine. TABLE1. Effects of antiarrhythmic compounds on epinephrine-induced arrhythmias in cats 1) Incidence of arrhythmias/no. of animals 2) Mean value ± standard error 552 M. UEDA ET AL. FIG. 2. Antiarrhythmic effects of aprindine, lidocaine, and propranolol on epine phrine-induced arrhythmias in cats. Numerals in each column indicate the incidence of ventricular arrhythmias. No antiarrhythmic effects were noticed for aprindine, lidocaine, and ajmaline even at their maximal dose, although marked antiarrhythmic effects were observed using pre treatment of propranolol (0.5 mg/kg, i.v.) and quinidine (10 mg/kg, i.v.) and some effects using procaine amide (Table 1, Fig. 2). Effects on ouabain arrhytlnnias in cats By cumulative intravenous administration of ouabain at doses of 60-75 '"g/kg, sinus rhythm was converted to ventricular rhythm via ventricular extrasystole in 6 control cats (Fig. 3). The ventricular rhythm continued for more than 3 hr in 3 cats and for about 1 hr in the other 3. In the latter group, cardiac arrest was observed after ventricular flutter or fibrillation. Spontaneous recovery from ventricular rhythm to sinus rhythm was not ANTIARRHYTHMIC EFFECT OF APRINDINE 553 observed. Intravenous infusion of antiarrhythinic compounds: Recovery from ventricular rhythm to sinus rhythm was observed with the intravenous infusion of aprindine (200 pg/kg/min, 5-7 mg/kg) in 3 out of 8 cats (Table 2). The established sinus rhythm continued for more FIG. 3. Ouabain-induced arrhythmias in cats. B : Before, SR: Sinus rhythm, VES : Ventricular extrasystole, VR : Ventricular rhythm, VF: Ventricular flutter, VFi: Ventricular fibrillation. TABLE 2. Effects of intravenous infusion of aprindine, lidocaine, and propranolol on ouabain-induced arrhythmias in cats 1) Mean value '-standard error 2) No. of antiarrhythmic effects/no. of animals 3) Duration of antiarrhythmic effects than 2 hr. Further infusion of aprindine was discontinued, because the characteristic pattern of ECG II by the cardiotoxic doses of aprindine-some notch on R spike, irregular height of R spike, widening of QRS complex, and depression of ST segment was observed. Lidocaine infusion (400 Pg/kg/min, 15-20 mg/kg) converted ventricular rhythm to sinus rhythm in all experiments and the established sinus rhythm was stable for more than 2 hr. Propranolol (200 pg/kg/min, 3-5 mg/kg) also caused recovery of sinus rhythm from marked arrhythmias in 4 out of 5 cats. In one cat, however, incomplete recovery to sinus rhythm with ventricular extrasystole was observed. Oral administration of antiarrhytlunic compounds: Although lidocaine did not show any antiarrhythmic activity, propranolol (20 mg/kg) converted ventricular rhythm to sinus rhythm in all cats even by oral administration. On the other hand, antiarrhythmic effects of aprindine (10, 20 mg/kg) and ajmaline (20 mg/kg) were incomplete as shown at Table 3. 554 M. UEDA ET AL. TABLE3. Effects of oral administration of aprindine, lidocaine, propranolol, and ajmaline on ouabain-induced arrhythmias in cats 1) No. of
Load more

Recommended publications
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Ventricular Tachycardia Drugs Versus Devices John Camm St
    Cardiology Update 2015 Davos, Switzerland: 8-12th February 2015 Ventricular Arrhythmias Ventricular Tachycardia Drugs versus Devices John Camm St. George’s University of London, UK Imperial College, London, UK Declaration of Interests Chairman: NICE Guidelines on AF, 2006; ESC Guidelines on Atrial Fibrillation, 2010 and Update, 2012; ACC/AHA/ESC Guidelines on VAs and SCD; 2006; NICE Guidelines on ACS and NSTEMI, 2012; NICE Guidelines on heart failure, 2008; NICE Guidelines on Atrial Fibrillation, 2006; ESC VA and SCD Guidelines, 2015 Steering Committees: multiple trials including novel anticoagulants DSMBs: multiple trials including BEAUTIFUL, SHIFT, SIGNIFY, AVERROES, CASTLE- AF, STAR-AF II, INOVATE, and others Events Committees: one trial of novel oral anticoagulants and multiple trials of miscellaneous agents with CV adverse effects Editorial Role: Editor-in-Chief, EP-Europace and Clinical Cardiology; Editor, European Textbook of Cardiology, European Heart Journal, Electrophysiology of the Heart, and Evidence Based Cardiology Consultant/Advisor/Speaker: Astellas, Astra Zeneca, ChanRX, Gilead, Merck, Menarini, Otsuka, Sanofi, Servier, Xention, Bayer, Boehringer Ingelheim, Bristol- Myers Squibb, Daiichi Sankyo, Pfizer, Boston Scientific, Biotronik, Medtronic, St. Jude Medical, Actelion, GlaxoSmithKline, InfoBionic, Incarda, Johnson and Johnson, Mitsubishi, Novartis, Takeda Therapy for Ventricular Tachycardia Medical therapy Antiarrhythmic drugs Autonomic management Ventricular tachycardia Monomorphic Polymorphic Ventricular fibrillation Ventricular storms Ablation therapy Device therapy Surgical Defibrillation Catheter Antitachycardia pacing History of Antiarrhythmic Drugs 1914 - Quinidine 1950 - Lidocaine 1951 - Procainamide 1946 – Digitalis 1956 – Ajmaline 1962 - Verapamil 1962 – Disopyramide 1964 - Propranolol 1967 – Amiodarone 1965 – Bretylium 1972 – Mexiletine 1973 – Aprindine, Tocainide 1969 - Diltiazem 1975- Flecainide 1976 – Propafenone Encainide Ethmozine 2000 - Sotalol D-sotalol 1995 - Ibutilide (US) Recainam 2000 – Dofetilide US) IndecainideX Etc.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • King's Research Portal
    King’s Research Portal DOI: 10.1503/cmaj.160355 Document Version Other version Link to publication record in King's Research Portal Citation for published version (APA): Trifirò, G., De Ridder, M., Sultana, J., Oteri, A., Rijnbeek, P., Pecchioli, S., Mazzaglia, G., Bezemer, I., Garbe, E., Schink, T., Poluzzi, E., Frøslev, T., Molokhia, M., Diemberger, I., & Sturkenboom, M. C. J. M. (2017). Use of azithromycin and risk of ventricular arrhythmia. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 189(15), E560-E568. https://doi.org/10.1503/cmaj.160355 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Review of Existing Classification Efforts
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.1.1 Review of existing classification efforts Due date of deliverable: (15.01.2008) Actual submission date: (07.02.2008) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UGent Revision 1.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Task 4.1 : Review of existing classification efforts Authors: Kristof Pil, Elke Raes, Thomas Van den Neste, An-Sofie Goessaert, Jolien Veramme, Alain Verstraete (Ghent University, Belgium) Partners: - F. Javier Alvarez (work package leader), M. Trinidad Gómez-Talegón, Inmaculada Fierro (University of Valladolid, Spain) - Monica Colas, Juan Carlos Gonzalez-Luque (DGT, Spain) - Han de Gier, Sylvia Hummel, Sholeh Mobaser (University of Groningen, the Netherlands) - Martina Albrecht, Michael Heiβing (Bundesanstalt für Straßenwesen, Germany) - Michel Mallaret, Charles Mercier-Guyon (University of Grenoble, Centre Regional de Pharmacovigilance, France) - Vassilis Papakostopoulos, Villy Portouli, Andriani Mousadakou (Centre for Research and Technology Hellas, Greece) DRUID 6th Framework Programme Deliverable D.4.1.1. Revision 1.0 Review of Existing Classification Efforts Page 2 of 127 Introduction DRUID work package 4 focusses on the classification and labeling of medicinal drugs according to their influence on driving performance.
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • Ethmozine and Ethacizine - New Antiarrhythmic Drugs with Defibrillating Properties
    ETHMOZINE AND ETHACIZINE - NEW ANTIARRHYTHMIC DRUGS WITH DEFIBRILLATING PROPERTIES Dalia Varon, Moshe Rechavi, Mordechai Erez, Gabriella Goldberg, Mordechai Manoach and Natalia V. Kaverina* Department of Physiology and Pharmacology, Tel Aviv University School of Medicine, Tel-Aviv, Israel *Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia ABSTRACT Ventricular fibrillation (VF) is a life-threatening arrhythmia that leads to death unless electrical defibrillation is applied in time. Recent publications indicate that VF can be either sustained (SVF), requiring electrical defibrillation, or transient (TVF), reverting spontaneously into sinus rhythm. Since VF cannot be totally prevented by drugs, a new antiarrhythmic therapeutic approach has been proposed: drug- induced enhancement of the ability of the heart to defibrillate by itself. In this study we examined the defibrillating potency of two antiarrhythmic phenothiazines, ethmozine (ETM) and ethacizine (ETA), as well as their effects on catecholamine uptake and on the electrophysiological properties of the myocardial cell membrane. The antiarrhythmic-defibrillatory activity was examined in cats; the inhibitory effect on [3H]-norepinephrine (NE) uptake was examined in rat brain synaptosomes, and the electrophysiological membrane effects were examined by microelectrode recordings in perfused strips of heart ventricle from guinea-pigs. The results indicate that: 1. ETA exhibits similar but stronger antiarrhythmic-defibrillating and NE reuptake inhibitory effects than ETM; 2. ETA at ΙΟ-6 Μ decreases ventricular conduction time and increases Vmax while ETM at this concentration does not change them; 3. The defibrillating ability of the drugs can be related to their inhibitory potency on NE reuptake. Accepted 8 August 1993 © FREUND PUBLISHING HOUSE LTD., 1993 299 Vol.
    [Show full text]
  • Suppression of Refractory Arrhythmias by Aprindine in Patients with the Wolff-Parkinson-White Syndrome1 PHILIP R
    Br Heart J: first published as 10.1136/hrt.39.12.1353 on 1 December 1977. Downloaded from British Heart Journal, 1977, 39, 1353-1360 Suppression of refractory arrhythmias by aprindine in patients with the Wolff-Parkinson-White syndrome1 PHILIP R. REID, H. LEON GREENE, AND P. JACOB VARGHESE From the Johns Hopkins University, Department of Medicine, Divisions of Cardiology and Clinical Pharmacology, Baltimore, Maryland, U.S.A. Four patients with supraventricular tachycardia associated with the Wolff-Parkinson-White syndrome were refractory to conventional pharmacological therapy and received aprindine hydrochloride intravenously and orally. Electrophysiological studies disclosed that intravenous aprindine caused increased refractoriness and slowed conduction in the atria, atrioventricular node, ventricles, and accessory pathway. The ability to induce supraventricular tachycardia with timed atrial and ventricular premature stimuli was totally abolished in all 4patients after intravenous aprindine. Oral aprindine therapy, twice daily thereafter, provided sympto- matic relief of the supraventricular tachycardia without significant side effects. Aprindine is useful in the management of supraventricular tachycardia associated with Wolff-Parkinson-White and may offer signifi- cant advantages over currently available therapy. copyright. Manifestations of the Wolff - Parkinson - White electrophysiological actions resembling quinidine (WPW) syndrome range from an electrocardio- (Elharrar et al., 1975; Steinberg and Greenspan, graphic curiosity in asymptomatic patients to re- 1976). current, disabling, and life-threatening arrhythmias We recently evaluated aprindine hydrochloride in in others. Worsening of congestive heart failure, 4 patients with accessory conduction syndromes precipitation of angina pectoris, and sudden death who were disabled by recurrent supraventricular http://heart.bmj.com/ have been reported in association with the tachy- tachycardia which was refractory to conventional arrhythmias of the WPW syndrome (Wood et al., medical management.
    [Show full text]
  • Drug/Substance Trade Name(S)
    A B C D E F G H I J K 1 Drug/Substance Trade Name(s) Drug Class Existing Penalty Class Special Notation T1:Doping/Endangerment Level T2: Mismanagement Level Comments Methylenedioxypyrovalerone is a stimulant of the cathinone class which acts as a 3,4-methylenedioxypyprovaleroneMDPV, “bath salts” norepinephrine-dopamine reuptake inhibitor. It was first developed in the 1960s by a team at 1 A Yes A A 2 Boehringer Ingelheim. No 3 Alfentanil Alfenta Narcotic used to control pain and keep patients asleep during surgery. 1 A Yes A No A Aminoxafen, Aminorex is a weight loss stimulant drug. It was withdrawn from the market after it was found Aminorex Aminoxaphen, Apiquel, to cause pulmonary hypertension. 1 A Yes A A 4 McN-742, Menocil No Amphetamine is a potent central nervous system stimulant that is used in the treatment of Amphetamine Speed, Upper 1 A Yes A A 5 attention deficit hyperactivity disorder, narcolepsy, and obesity. No Anileridine is a synthetic analgesic drug and is a member of the piperidine class of analgesic Anileridine Leritine 1 A Yes A A 6 agents developed by Merck & Co. in the 1950s. No Dopamine promoter used to treat loss of muscle movement control caused by Parkinson's Apomorphine Apokyn, Ixense 1 A Yes A A 7 disease. No Recreational drug with euphoriant and stimulant properties. The effects produced by BZP are comparable to those produced by amphetamine. It is often claimed that BZP was originally Benzylpiperazine BZP 1 A Yes A A synthesized as a potential antihelminthic (anti-parasitic) agent for use in farm animals.
    [Show full text]
  • Side Effects
    PHARMACEUTICAL CHEMISTRY ANTIBIOTICS (Classification and uses) CATEGORIES Penicillin and derivatives eg Benzyl penicillin(Penicillin G), Phenoxy methyl penicillin(Penicillin V), Ampicillin, Amoxicillin, Cloxacillin, Oxacillin Cephalosporins eg Cephaloglycin, Cephelexin, Cefazolin, Cefaclor, Cefuroxime, Cefadroxil, Ceftriaxone, Cephaloridine. Polypeptide Antibiotics eg Amphotericin B, Nystatin, Polymyxin B, Actinomycin D Aminoglycoside Antibiotics eg Gentamycin, Kanamycin, Tobramycin, Amikacin, Tobramycin, Neomycin Tetracyclines Antibiotics Chlortetracycline Macrolides Antibiotics Erythromycin, Azithromycin, Clarithromycin Fluoroquinolones Antibiotics Ciprofloxacin, Ofloxacin, Gatifloxacin, Norfloxacin, Levofloxacin. Steroidal antibiotics fusidic Acid AMINOGLYCOSIDES Amikacin Gentamycin Kanamycin Neomycin Netilimicin Tobramycin Promomycin streptomycin COMMON USES Infections caused by Gram-negative bacteria, such as Escherichia coli and Klebsiella particularly Pseudomonas aeruginosa. Effective against aerobic bacteria (not obligate/facultative anaerobes) and tularemia. All aminoglycosides are ineffective when taken orally as the stomach will digest the drug before it goes into the bloodstream. However aminoglycosides are effective in Intravenous, intramuscular and topical forms. Tuberculosis, Gonorrhea POSSIBLE SIDE EFFECTS Hearing loss Vertigo Kidney damage Stomach upset Loss of appetite Fever Rash Neurotoxicity Ototoxicity Nausea Vomitting ANSAMYCINS Geldanamycin Herbimycin Rifaximin Uses of Ansamycins:-
    [Show full text]